News >

Expert Discusses Challenges With Non-Driver Lung Adenocarcinoma

Gina Columbus @ginacolumbusonc
Published: Friday, Dec 23, 2016

And, community radiation oncologists, medical oncologists, interventional radiologists, and pathologists need to all be sitting in 1 room—rather than be making these decisions in isolation. Universities and institutions may have tumor boards, but there needs to be a tumor board available for every practice. We are at that point now.

You mentioned there being too many ongoing clinical trials. How can the oncology community overcome that?

I don’t think it will be overcome by any 1 factor. This is because everybody has their own compound and their own vested interest. They are not interested in helping someone else’s compound. Consortiums of physicians, cooperative groups—even the National Cancer Institute—can align incentives in a way so that the trials are prioritized. Then, somehow there could be centralized clearing mechanisms in which it automatically happens that the best study and the best design survives—and poor studies and poor designs do not survive.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x